SRI developed halofantrine for the U.S. Army from 1965 to 1975 as a treatment for drug-resistant malaria. Distributed by the World Health Organization (WHO), the drug has saved countless lives. The Food and Drug Administration (FDA) approved halofantrine as an antimalarial in 1992 under the SmithKline Beecham (now GlaxoSmithKline) brand name, Halfan®.
SRI’s work on DARPA’s HAPPI program seeks to measurably advance the capability of circuits that transmit information using light rather than electrons.
To chart the future of human-machine teaming, SRI’s COLLEAGUE project is building an AI-based system designed to act as a true collaborative partner.
SRI CEO David Parekh among top global leaders contributing expertise on how technology will impact the future.